# Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections

> **NCT00210899** · PHASE3 · COMPLETED · sponsor: **Basilea Pharmaceutica** · enrollment: 828 (actual)

## Conditions studied

- Skin Diseases, Infectious
- Skin Diseases, Bacterial
- Staphylococcal Skin Infections

## Interventions

- **DRUG:** ceftobiprole medocaril
- **DRUG:** Vancomycin plus Ceftazidime

## Key facts

- **NCT ID:** NCT00210899
- **Lead sponsor:** Basilea Pharmaceutica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 828 (ACTUAL)
- **Last updated:** 2012-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00210899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00210899, "Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00210899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*